

AI-Guided Personalized Gut Microbiome Modulation for Persistent Secondary Gastrointestinal Symptoms in Oncology Patients

Cancers (MDPI), 2025
<https://www.mdpi.com/2072-6694/18/9/1453>

Design	Prospective validation study in cancer patients with persistent GI symptoms after treatment.
Intervention	Three months of AI-generated individualized dietary and supplement recommendations.
Reported outcome	Improvement in bowel habits and energy; favourable shifts in beneficial gut bacteria (notably Bifidobacterium longum) and related metabolic markers.
Interpretation	Microbiome compositional findings are exploratory unless stated otherwise in the publication.

Scope of this document

This is a one-page orientation to the study design and reported outcomes. It is not a substitute for the publication. Full eligibility criteria, endpoint definitions, assay methods, statistical analysis, confidence intervals, ethics approval, funding and declared conflicts of interest are given in the peer-reviewed paper linked above.

Limitations that apply to this study

The study is not a randomised controlled trial. Without a control arm, placebo response, regression to the mean and selection effects cannot be separated from the intervention effect. Patient-reported outcomes are subjective. Results describe the population studied and should not be extrapolated beyond it.

Requests for analysis-level data or a protocol review: research@nostrabiome.ai

Methodology questions are answered at nostrabiome.ai/research-faq